NTRB — NutriBand Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1676047 ·
Last close
$3.48
Market Cap
$42.36M
52W High
$4.45
52W Low
$3.40
ADV30
9,328
Next earnings
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jan 2026 400,709 88,941 -1,020,915 -968,059 7,547,935 4,574,857 868,447
Oct 2025 346,058 68,505 -3,880,336 -3,872,367 8,419,160 5,312,177 870,208
Jul 2025 622,452 156,881 -2,003,213 -2,000,337 10,176,588 6,995,101 1,682,780
Apr 2025 667,432 251,981 -1,413,497 -1,388,869 6,152,181 2,964,097 1,048,795

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,134,630
Investing CF
$-5,324
Financing CF
$5,403,092
CapEx
$-52,282
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.68
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-46,692,268
Inventory
$117,987
Receivables
$118,404
ST Investments
EBIT TTM
$-8,207,097
Pretax Income TTM
$-8,229,632
Interest Exp TTM
$22,535
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,036,651
EBITDA
$-8,124,164
Free Cash Flow
$-2,449,000
Enterprise Value
$39,921,420
Total Cash
$4,574,857
Total Debt
$245,490
Shares Out
12,155,983
Trailing EPS
$-2.58
Book Value
$0.55
ROE
-125.6%
ROA
-69.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Jan 2026 2,036,651 -8,317,961 -8,229,632 7,547,935 868,447 -5,134,630
Jan 2025 2,139,537 -6,689,627 -10,482,617 7,469,955 1,041,050 -4,626,564
Jan 2024 2,085,314 -4,871,926 -5,485,314 7,517,154 1,078,919 -3,527,509
Jan 2023 2,079,609 -4,147,859 -4,483,474 9,456,377 883,387 -2,987,198

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.23

Peers — same industry

TickerNameMarket CapLastDaily %
PAVM PAVmed Inc. $43.96M $6.14
NSPR InspireMD, Inc. $44.50M $0.95
VASO VASO Corp $40.30M $0.23
ARAY ACCURAY INC $44.56M $0.37
MYO MYOMO, INC. $39.80M $1.03

News headlines (Yahoo Finance, 1h cache)

Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
2026-05-15 11:00 · Yahoo
Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
2026-04-22 11:00 · Yahoo
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
2026-03-30 20:05 · Yahoo
Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica
2026-03-18 11:00 · Yahoo
Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica
2026-02-17 12:28 · Yahoo
Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
2026-01-30 12:00 · Yahoo
The past five years for Nutriband (NASDAQ:NTRB) investors has not been profitable
2026-01-29 19:59 · Yahoo
Nutriband says ‘committed’ to shareholder value as ‘number one focus’
2026-01-01 12:10 · Yahoo
Nutriband CEO Publishes Letter to Shareholders
2025-12-31 12:00 · Yahoo
Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
2025-12-29 14:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.